טוען...
Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?
The use of rituximab for the treatment of immune thrombocytopenia was greeted enthusiastically: it led to up to 60% response rates, making it, nearly 20 years ago, the main alternative to splenectomy, with far fewer side effects. However, long-term follow-up data showed that only 20-30% of patients...
שמור ב:
| הוצא לאור ב: | Haematologica |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Ferrata Storti Foundation
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6545833/ https://ncbi.nlm.nih.gov/pubmed/31126963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.218883 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|